Lupin Limited appoints Abdelaziz Toumi as CEO of new subsidiary

Global pharmaceutical giant, Lupin Limited, announced the appointment of Abdelaziz Toumi (commonly known as Abdel) as the Chief Executive Officer of its newly established subsidiary, Lupin Manufacturing Solutions (LMS). Based in Switzerland, Abdel brings a robust mix of scientific and commercial expertise to LMS, which is set to spearhead the development, manufacture, and sale of Active Pharmaceutical Ingredients (APIs). The subsidiary is also venturing into Contract Development and Manufacturing Operations (CDMO) to enhance its service offerings.

Abdelaziz Toumi is a seasoned leader with more than two decades of experience in the biotech, pharmaceutical, and CDMO sectors across Europe, North America, and Asia. His career includes significant leadership roles at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was instrumental in driving growth, fostering innovation, and ensuring operational excellence. Abdel’s educational background is equally impressive, holding a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland.

LMS is poised to play a crucial role in Lupin’s strategy to expand its manufacturing and service capacity in the high-stakes API and CDMO markets. This move is expected to enhance Lupin’s ability to meet the growing global demand for pharmaceutical products and solutions, positioning the company as a trusted partner in the pharmaceutical manufacturing sector.

Nilesh Gupta, Managing Director of Lupin, expressed enthusiasm about Abdel’s appointment, stating, “We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”

Lupin is an innovation-led transnational pharmaceutical company with a strong presence in over 100 markets, including the U.S., India, South Africa, and various regions across Asia Pacific, Latin America, Europe, and the Middle East. The company is renowned for its leadership in cardiovascular, anti-diabetic, and respiratory segments and maintains a robust presence in the anti-infective, gastrointestinal, central nervous system, and women’s health areas. Notably, Lupin is ranked as the third-largest pharmaceutical company in the U.S. by prescriptions. Demonstrating a strong commitment to innovation, Lupin invested 7.8% of its revenue in research and development in the fiscal year 2024.

Lupin operates 15 manufacturing sites and 7 research centers worldwide, employing over 20,000 professionals. The establishment of LMS underlines Lupin’s ongoing strategy to enhance its manufacturing capabilities and reinforce its position in the global pharmaceutical industry.